Bianchi, Giulia Val
Fondazione IRCCS Istituto Nazionale dei Tumori
3 papers on CoChatORCID 0000-0003-3630-4527
Most cited papers
- Verified
Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 1,121
- Verified
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 865
- Verified
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Breast Cancer Research
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 83
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free